Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Inhibition of Human Liver Cytochrome P-450 1A2 by the Class IB Antiarrhythmics Mexiletine, Lidocaine, and Tocainide

Xiaoxiong Wei, Renke Dai, Suoping Zhai, Kenneth E. Thummel, Fred K. Friedman and Robert E. Vestal
Journal of Pharmacology and Experimental Therapeutics May 1999, 289 (2) 853-858;
Xiaoxiong Wei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renke Dai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suoping Zhai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth E. Thummel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred K. Friedman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert E. Vestal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Mexiletine, lidocaine, and tocainide are class IB antiarrhythmic drugs that are used for the treatment of ventricular arrhythmias and are known to inhibit drug metabolism. The objectives of this study were to characterize the inhibitory effects of mexiletine, lidocaine, and tocainide on cytochrome P-450 1A2 (CYP1A2) activity in human liver microsomes and to evaluate their relative inhibitory potencies by using a molecular model of this P-450 isozyme. The inhibitory effect of mexiletine, lidocaine, and tocainide on cytochrome CYP1A2 in human liver microsomes was examined with methoxyresorufinO-demethylase activity as an index of the catalytic activity of this P-450 isozyme. The kinetic inhibition types andK i values were determined by Lineweaver-Burk plots and Dixon plots, respectively. Molecular modeling was used to assess the interaction of these agents with the CYP1A2 active site. Methoxyresorufin O-demethylase activity was inhibited 67 ± 8%, 20 ± 5%, and 7 ± 4% by 2 mM mexiletine, lidocaine, and tocainide, respectively. Mexiletine and lidocaine exhibited competitive inhibition with K ivalues of 0.28 ± 0.12 mM and 1.54 ± 0.74 mM, respectively, whereas the inhibition type of tocainide could not be determined because of its weak potency. A charge interaction between mexiletine and the Asp313 side chain in the CYP1A2 active site was found, and varying degrees of hydrogen bond formation between these three compounds and the CYP1A2 active site were observed. The in vitro inhibitory potencies in human liver microsomes (mexiletine > lidocaine > tocainide) are consistent with the structural interactions found in a molecular model of the active site of CYP1A2.

Footnotes

  • Send reprint requests to: Robert E. Vestal, M.D., Covance Clinical and Periapproval Services Inc., 2121 N. California Blvd., Suite 500, Walnut Creek, CA 94596. E-mail: bob.vestal{at}covance.com

  • ↵1 This work was supported by the Department of Veterans Affairs (Office of Research and Development, Medical Research Service), the National Institutes of Health (National Cancer Institute), and the Mountain States Medical Research Institute.

  • ↵2 Present address: Office of Pharmaceutical Sciences, U.S. Food and Drug Administration, HFD-870,13B-17, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.

  • ↵3 Present address: Clinical Pharmacokinetics Unit, Cellular and Clinical Pharmacology Section, National Cancer Institute, National Institutes of Health, Building 10, Room 5A-01, 9000 Rockville Pike, Bethesda, MD 20892.

  • ↵4 Present address: Covance Clinical and Periapproval Services Inc., 2121 N. California Blvd., Suite 500, Walnut Creek, CA 94596.

  • Abbreviations:
    CYP1A2
    cytochrome P-450 1A2
    MROD
    methoxyresorufin O-demethylase
    • Received July 16, 1998.
    • Accepted December 3, 1998.
  • U.S. Government
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 289 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 289, Issue 2
1 May 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of Human Liver Cytochrome P-450 1A2 by the Class IB Antiarrhythmics Mexiletine, Lidocaine, and Tocainide
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inhibition of Human Liver Cytochrome P-450 1A2 by the Class IB Antiarrhythmics Mexiletine, Lidocaine, and Tocainide

Xiaoxiong Wei, Renke Dai, Suoping Zhai, Kenneth E. Thummel, Fred K. Friedman and Robert E. Vestal
Journal of Pharmacology and Experimental Therapeutics May 1, 1999, 289 (2) 853-858;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Inhibition of Human Liver Cytochrome P-450 1A2 by the Class IB Antiarrhythmics Mexiletine, Lidocaine, and Tocainide

Xiaoxiong Wei, Renke Dai, Suoping Zhai, Kenneth E. Thummel, Fred K. Friedman and Robert E. Vestal
Journal of Pharmacology and Experimental Therapeutics May 1, 1999, 289 (2) 853-858;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
  • Is Hydroxylamine-Induced Cytotoxicity a Valid Marker for Hypersensitivity Reactions to Sulfamethoxazole in Human Immunodeficiency Virus-Infected Individuals?
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics